• about us
• allosteric modulation
• pipeline
  • discovery pipeline
• key indications
• business development
• investor center
• press releases
• careers
• contact

mGluR2 PAM

Addex is developing mGluR2 PAM under a 2004 collaboration agreement with Johnson & Johnson. Several series of mGluR2 PAMs were discovered and some are in late lead optimization. In 2007 Addex completed its responsibilities in the discovery phase of the agreement. Preclinical and clinical development are Johnson & Johnson’s responsibility, although Addex will participate via a joint steering committee. Addex is eligible for undisclosed milestone and royalty payments. Other indications for mGluR2 PAM include anxiety.


Back to discovery pipeline